DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RIVASTIGMINE
Clinical Trials for Rivastigmine
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00099216 | Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia | Completed | Novartis Pharmaceuticals | Phase 3 | The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia. |
| NCT00099242 | Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease | Completed | Novartis | Phase 3 | The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease. |
| NCT00102284 | Neuromodulation and Language Acquisition (Project Stage Ia) | Terminated | University Hospital Muenster | Phase 4 | The purpose of this study is to determine whether levodopa, pergolid, rivastigmine, or modafinil are effective in boosting semantic language acquisition in healthy subjects. |
| NCT00102856 | Neuromodulation and Language Acquisition (Stage Ib) | Suspended | University Hospital Muenster | Phase 4 | The purpose of this study is to determine whether rivastigmine or pramipexol are effective in boosting semantic language acquisition in healthy subjects. |
| NCT00130338 | Rivastigmine Capsules in Patients With Probable Vascular Dementia | Completed | Novartis | Phase 3 | The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia. |
| NCT00134953 | Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment | Terminated | Novartis | Phase 3 | This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI). |
| NCT00154635 | Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease | Unknown status | Development Center for Biotechnology, Taiwan | Phase 2 | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer’s Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Rivastigmine
Condition Name
Condition MeSH
Clinical Trial Locations for Rivastigmine
Trials by Country
Clinical Trial Progress for Rivastigmine
Clinical Trial Phase
Clinical Trial Sponsors for Rivastigmine
Sponsor Name
